Rapport Therapeutics is a biotechnology research startup based in Boston, Massachusetts that recently raised $120M in Series A funding. The company is founded by Abraham (Abe) Ceesay, and its investors include Johnson & Johnson, ARCH Venture Partners, and Third Rock Ventures. Rapport's mission is to create impactful neuro medicines with fewer side effects that allow patients and their families to live healthier and more fulfilling lives. They believe that precision neuro medicines will improve lives by overcoming the limitations of today's treatments for many neurological conditions. Their approach is to use their deep understanding of the intricate relationships between receptors, their associated proteins, and their distributions in specific cell types and brain regions to precisely direct medicines to the neural circuits underlying disease pathophysiology.

Rapport Therapeutics' strengths lie in their founding scientists' expertise in the biologic and therapeutic applications of receptor-associated proteins (RAPs). The company's co-founder and CSO, David Bredt, pioneered RAP discovery more than two decades ago while working at Janssen Neuroscience. Alongside many other scientific leaders, he advanced the idea of harnessing RAPs to target specific neuron circuits. Seeing an opportunity to house this technology in a biotech company, Janssen and Third Rock Ventures partnered to create Rapport in late 2022. Their first program, currently in Phase I clinical development, is designed to treat drug-resistant seizure disorders.